Business
GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-5550 TriKE®, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors Expressing B7-H3
GTB-5550 Phase 1 dose escalation basket trial expected to initiate mid-2026 Phase 1 protocol allows multiple solid tumor types known to express B7-H3 Unaudited proforma cash balance as of January 31, 2026 of approximately $9 million anticipated to extend cash runway through Q4 2026 SAN FRANCISCO, CALIFORNIA, Feb. 03, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Compa
About this update from Gt Biopharma, Inc.
[{"type":"image","alt":"GT Biopharma, Inc.","displaySize":"","headline":null,"caption":"GT Biopharma, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":215,"height":99,"url":"https://media.zenfs.com/en/globenewswire.com/2255bf0b7d4c7ce859ad7c63f5fbd6ee"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/tMyfq5DvA9tFDyIoDXVIwQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5MztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/2255bf0b7d4c7ce859ad7c63f5fbd6ee","width":215,"height":99}},"lazy":false},{"type":"text","content":"GTB-5550 Phase 1 dose escalation basket trial expected to initiate mid-2026","length":75,"tagName":"p"},{"type":"text","content":"Phase 1 protocol allows multiple solid tumor types known to express B7-H3","length":73,"tagName":"p"},{"type":"text","content":"Unaudited proforma cash balance as of January 31, 2026 of approximately $9 million anticipated to extend cash runway through Q4 2026","length":132,"tagName":"p"},{"type":"text","content":"SAN FRANCISCO, CALIFORNIA, Feb. 03, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer (NK) cell engager platform, today announced FDA clearance of its IND application for GTB-5550, allowing the company to proceed with a Phase 1 clinical trial, which is anticipated to initiate in mid-2026.","length":468,"tagName":"p"},{"type":"text","content":"“FDA clearance of our third TriKE® IND, GTB-5550, represents a defining moment for GT Biopharma as we bring another NK cell engager into the clinic”, said Michael Breen, Executive Chairman and Chief Executive Officer of GT Biopharma. “We expect to commence enrollment of the Phase 1 basket trial in mid-2026. While the phase I trial is open to patients with common solid tumors that express B7-H3, in the dose-escalation component we will prioritize enrollment for advanced prostate, ovarian, and pancreatic cancer patients who have failed standard therapies. Based on the encouraging trends we have seen from our ongoing Phase 1 trial with GTB-3650 in AML patients, we are even more enthusiastic about the potential benefits of GTB-5550 treatment in patients with solid tumors known to express B7-H3.”","length":802,"tagName":"p"},{"type":"text","content":"GTB-5550 is a ca...